• May 1. FDA approves pancrelipase (Creon Delayed-Release Capsules) for adult and pediatric patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), chronic pancreatitis, and other conditions. Drug information
• April 30. FDA updates the Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B). Information
• April 22. FDA updates action on Plan B (levonorgestrel) tablets. FDA Statement
• April 14. FDA imposes restrictions on Coast IRB due to violations. FDA News
• April 14. FDA issues Information for Healthcare Professionals: Ceftriaxone (marketed at Rocephin and generics) Information
• April 8. Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announces that it has begun a voluntary, phased withdrawal of the product from the U.S. market. FDA Statement
